Jeremy Levin is the Global Head of Strategic Alliances for the Novartis Institutes for BioMedical Research.
 

In this position Jeremy is responsible both for evaluating and managing current alliances with academia and biotechnology, interfacing with the venture community and establishing strategic collaborations to further the research mission of NIBR.
 

From 1996 to 2000, Jeremy served as the Chairman of Physiome Sciences, Inc., and was appointed as Physiome's President and Chief Executive Officer in 2000. From 1998 through 1999 he was Managing Director of Perseus Capital LLC and from 1992 to 1998, he served as the President and Chief Executive Officer of Cadus Pharmaceutical Corporation, where he also served as Chairman from 1996 to 1998. Prior to 1992, Jeremy was a Vice President at IG Laboratories, a wholly owned subsidiary of Genzyme Corporation. In these positions, he developed and lead multiple collaborations with partners from academia, biotech through to major pharmaceutical companies.
 

Jeremy Levin has served on the Executive Committees and Boards of several public biosciences companies, including the executive committee of BIO and the Boards of the Biotechnology Institute and the New York Biotechnology Association. Jeremy received an MB.BChir. from the University of Cambridge, UK and a D.Phil. in DNA structure from the University of Oxford, UK.